Modeling treatment-resistant depression
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Depression is a polygenic and highly complex psychiatric disorder that is currently a major burden on society. Depression is highly heterogeneous in presentation and frequently exhibits high co-morbidity with other psychiatric and somatic deficits. Commonly used treatments, such as selective serotonin reuptake inhibitors (SSRIs), are not ideal since only a subset of patients achieve remission. In addition, the reason why some individuals respond to SSRIs while others don’t are unknown. Here we begin to ask what the basis of treatment-resistance is, and propose new strategies to model this phenomenon in animals. We focus specifically on animal models that offer the appropriate framework to study treatment resistance with face, construct and predictive validity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059 · cited 1×
“The NMDA receptor antagonist ketamine, and the anti-cholinergic scopolamine, as well as deep brain stimulation, have been shown through multiple trials in the last decade to produce a rapid antidepressant response (Berman et al., 2000; Krystal, 2007; Mayberg et al., 2005; Zarate et al., 2006).”
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“As an example, only 47% of patients respond and only 33% of patients achieve remission in the first line of treatment with a widely used SSRI (Trivedi et al., 2006).”
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“Repeated defeats over 10 days can result in a long lasting reduced social interaction, sexual dysfunction, sleep dysregulation, anxiety, metabolic deficits and anhedonia (Berton et al., 2006; Krishnan et al., 2007; Krishnan and Nestler, 2008; Tsankova et al., 2006).”
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 4×
“Interestingly, recent work has demonstrated that in rats ketamine rapidly activates the mTOR pathway, leading to increased synaptic signaling proteins and an increased number of functional new synapses in the prefrontal cortex (Li et al., 2010).”
InfluentialKrishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307 · cited 3×
“Given that molecular mechanisms for resilience to the stressful procedure are now being worked out (Krishnan et al., 2007; Vialou et al., 2010), it would be intriguing to see if similar pathways are necessary for mediating response to antidepressants.”
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 1×
“Repeated defeats over 10 days can result in a long lasting reduced social interaction, sexual dysfunction, sleep dysregulation, anxiety, metabolic deficits and anhedonia (Berton et al., 2006; Krishnan et al., 2007; Krishnan and Nestler, 2008; Tsankova et al., 2006).”
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · cited 1×
“…a high comorbidity with co-occurrence rates up to 60% in patients (Gorman, 1996; Leonardo and Hen, 2006), they have generally been conceived of as distinct psychiatric disorders, believed to be caused by alterations of different brain circuits (Nestler and Hyman, 2010; Krishnan and Nestler, 2011).”
Willner, P., Towell, A., Sampson, D., Sophokleous, S., & Muscat, R. (1987) · Psychopharmacology · doi:10.1007/bf00187257 · Cited by 1,993 · cited 2×
“deprivation, small temperature reductions and changes of cage mates (Willner, 2005; Willner et al., 1987).”
Cited by
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
The role of 5-HT receptors in depression
Yohn, C. N., Gergues, M. M., & Samuels, B. A. (2017) · Molecular Brain · doi:10.1186/s13041-017-0306-y · Cited by 485
GABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
“These effects of stress can be prevented or reversed by antidepressant drug treatment (reviewed by Samuels et al., 2011).”
BackgroundSchwarz, E., Guest, P. C., Steiner, J., Bogerts, B., & Bahn, S. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.3 · Cited by 91
Towards translational rodent models of depression
O’Leary, O. F., & Cryan, J. F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1587-9 · Cited by 60
“Indeed, by using chronic mild stress or chronic corticosterone treatment as inducing factors, a bimodal response to escitalopram and fluoxetine has been reported (Jayatissa et al. 2006; Samuels et al. 2011).”
Background
Metadata
- Authors
- Samuels, B. A., Leonardo, E. D., Gadient, R., Williams, A., Zhou, J., David, D. J., Gardier, A. M., Wong, E. H. F., & Hen, R.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2011-09
- Volume
- 61
- Issue
- 3
- Pages
- 408-413
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2015536698
- Cited by
- 87
- References
- 23
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modeling treatment-resistant depression. https://app.cochat.ai/papers/10.1016/j.neuropharm.2011.02.017
- The paper
- Samuels, B. A., Leonardo, E. D., Gadient, R., Williams, A., Zhou, J., David, D. J., Gardier, A. M., Wong, E. H. F., & Hen, R. (2011). Modeling treatment-resistant depression. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2011.02.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.